Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method
- PMID: 29230490
- PMCID: PMC5778159
- DOI: 10.1007/s00210-017-1448-2
Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method
Abstract
Tianeptine is an atypical antidepressant with a unique mechanism of action and recently it has been also reported that its major metabolite, compound MC5, possesses pharmacological activity similar to that of the parent drug. The current study aims to investigate the pharmacokinetics (PK) of both tianeptine and MC5 after intravenous or intraperitoneal administration of the parent drug as well as the metabolic ratio of MC5 in rats. To achieve these goals an LC-MS/MS method using the small sample volume for the quantitation of tianeptine and its active metabolite MC5 in rat plasma and liver perfusate has been developed and validated. Following an intravenous administration of tianeptine pharmacokinetic parameters were calculated by non-compartmental analysis. The average tianeptine volume of distribution at steady state was 2.03 L/kg and the systemic clearance equaled 1.84 L/h/kg. The mean elimination half-lives of tianeptine and MC5 metabolite were 1.16 and 7.53 h, respectively. The hepatic clearance of tianeptine determined in the isolated rat liver perfusion studies was similar to the perfusate flow rate despite the low metabolic ratio of MC5. Mass spectrometric analysis of rat bile indicated that tianeptine and MC5 metabolite are eliminated with bile as glucuronide and glutamine conjugates. Bioavailability of tianeptine after its intraperitoneal administration was 69%. The PK model with a metabolite compartment developed in this study for both tianeptine and MC5 metabolite after two routes of administration may facilitate tianeptine dosage selection for the prospective pharmacological experiments.
Keywords: MC5 metabolite; Mass spectrometry; Pharmacokinetics; Rats; Tianeptine.
Conflict of interest statement
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All applicable international, national, and institutional guidelines for the care and use of animals were followed. All of the animal experiments described in this paper were approved by the Institutional Animal Care and Ethics Committee of the Jagiellonian University (nr 226/2015).
Figures







Similar articles
-
The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans--influence of alcohol co-administration.Fundam Clin Pharmacol. 1990;4(1):115-25. doi: 10.1111/j.1472-8206.1990.tb01021.x. Fundam Clin Pharmacol. 1990. PMID: 2341111
-
Kinetic profiles of tianeptine and its MC5 metabolite in plasma, blood and brain after single and chronic intraperitoneal administration in the rat.Eur J Drug Metab Pharmacokinet. 1990 Jan-Mar;15(1):69-74. doi: 10.1007/BF03190130. Eur J Drug Metab Pharmacokinet. 1990. PMID: 2384119
-
Tianeptine and its main metabolite. Disposition in chronic renal failure and haemodialysis.Fundam Clin Pharmacol. 1990;4(6):663-71. doi: 10.1111/j.1472-8206.1990.tb00046.x. Fundam Clin Pharmacol. 1990. PMID: 2096105
-
Neurochemical profile of tianeptine, a new antidepressant drug.Clin Neuropharmacol. 1988;11 Suppl 2:S43-50. Clin Neuropharmacol. 1988. PMID: 3052825 Review.
-
Tianeptine Abuse and Dependence in Psychiatric Patients: A Review of 18 Case Reports in the Literature.J Psychoactive Drugs. 2018 Jul-Aug;50(3):275-280. doi: 10.1080/02791072.2018.1438687. Epub 2018 Mar 1. J Psychoactive Drugs. 2018. PMID: 29494783 Review.
Cited by
-
Determination of Antidepressants in Human Plasma by Modified Cloud-Point Extraction Coupled with Mass Spectrometry.Pharmaceuticals (Basel). 2020 Dec 12;13(12):458. doi: 10.3390/ph13120458. Pharmaceuticals (Basel). 2020. PMID: 33322843 Free PMC article.
-
Interactions of antidepressants with concomitant medications-safety of complex therapies in multimorbidities.Pharmacol Rep. 2024 Aug;76(4):714-739. doi: 10.1007/s43440-024-00611-7. Epub 2024 Jul 16. Pharmacol Rep. 2024. PMID: 39012418 Free PMC article. Review.
References
-
- Bence C, Bonord A, Rebillard C, Vaast P, Alexandre C, Jardri R, Rolland B (2016) Neonatal abstinence syndrome following tianeptine dependence during pregnancy. Pediatrics 137(1). 10.1542/peds.2015-1414 - PubMed
-
- Carlhant D, Le Garrec J, Guedes Y, Salvadori C, Mottier D, Riche C. Pharmacokinetics and bioavailability of tianeptine in the elderly. Drug Investig. 1990;2(3):167–172. doi: 10.1007/BF03259191. - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources